Although the result showed the copy number of EGFR/ERBB2 showed a worse prognosis than the low copy number patients, the results showed no statistical significance between the copy number of EGFR/ERBB2 and the prognosis of ampullary adenocarcinoma (Supplementary Fig. S2o, p). This evidence concerns the gene EGFR and ampulla of vater adenocarcinoma.